Opinion
Video
Author(s):
Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC
Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
Five Under 5: Top Oncology Videos for the Week of 1/26
Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC
Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer
Dr Levy on the Development and Clinical Use of ADCs in NSCLC
Fox Chase Cancer Center’s Austin Williams Named 2025 Society of Surgical Oncology Presidential Scholar
CHMP Recommends Approval of Durvalumab for Limited-Stage Small Cell Lung Cancer
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer